Search Results - clinical+and+disease+specializations+%3e+immuno-oncology

18 Results

Sort By:

Antitumor drug interrupting glucose metabolism as a therapeutic strategy for cancer

Value Proposition:· Drug reduces tumor burden by interrupting cancer cells’ reliance on glucose metabolism.· Tolerated by healthy, normal cells.· Potential for combination therapy with other modalities (chemotherapy, radiation, immunotherapy, etc.) Technology Description· Researchers at Johns Hopkins have developed a drug to reduce...

Published: 5/10/2024 | Inventor(s): Ling He

Keywords(s):

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Nanoparticles for Delivery of Immunoregulatory Materials to T Cells

Value Proposition:· This platform improves current methods for expansion of CD4+ T-cells, which could be used in adoptive transfer therapies.· Improves modulation, activation, and expansion of T cells over current methods used for CAR T-cell therapyTechnology Description· Researchers at Johns Hopkins have developed a nanoparticle-based...

Published: 5/10/2024 | Inventor(s): Jonathan Schneck, Ariel Isser

Keywords(s):

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Engineering Tech, Technology Classifications > Therapeutic Modalities

Compositions of Kinetic Nanoparticles containing Nucleic Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same

Value Proposition:· Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads· Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity· Can be used for in vivo gene therapy delivery as well as in vitro cell transfection and research applications Technology...

Published: 5/10/2024 | Inventor(s): Hai-Quan Mao, Stephany Tzeng, Jordan Green, Yizong Hu, Sashank Reddy, Leonardo Cheng

Keywords(s):

VR-Expressing Cells against Multiple Cytokines and Uses Thereof

Unmet Need· Recent technological breakthroughs have highlighted the therapeutic potential of immunotherapy (e.g., CAR-T cells) and have focused attention and efforts on developing safe and effective immunotherapy modalities.· Despite advances in the field, there remain several challenges to both efficacy and safety of CAR-T and other immunotherapies.· CAR-T...

Published: 5/10/2024 | Inventor(s): Adrian Johnston, Denis Wirtz

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology

Engineered Extracellular Vehicles as a selective drug delivery platform

Value Proposition:· Engineered extracellular vesicles with enhanced uptake and reduced immunogenicity · Improved EV-based drug delivery platform Technology DescriptionResearchers at Johns Hopkins have identified endogenous proteins that can be engineered to assist in extracellular vesicle and/or nanoparticle therapeutics through increased...

Published: 5/10/2024 | Inventor(s): Kenneth Witwer, Zach Troyer

Keywords(s):

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Genetic Diseases, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics

Dendrimer-delivered alpha-particle radiotherapy for treatment of glioblastoma and possibly of other cancers in the brain

#C17436Inventor(s): Stavroula Sofou (primary), Kannan Rangaramanujam, Rajiv NairUnmet NeedGlioblastoma accounts for 49.1 percent of all primary malignant brain tumors. Although current standard of care, which includes surgery, followed by radiotherapy, and chemotherapy, may prolong survival, the five-year survival rate for glioblastoma patients is only...

Published: 5/10/2024 | Inventor(s): Stavroula Sofou, Kannan Rangaramanujam, Rajiv Nair

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Glioblastoma, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Immuno-Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Neutrophil Suppression as Preconditioning to Increase Efficacies and Safety of Oncolytic Bacterial Therapies

Unmet NeedHypoxia is a prominent feature of solid tumors and can function as fertile environment for oncolytic anaerobic bacteria such as Clostridium novyi-NT (C. novyi-NT) where it can induce tumor destruction in mice and patients. However, two major obstacles have limited its use, namely the host inflammatory response and the incomplete clearance...

Published: 5/10/2024 | Inventor(s): Renyuan Bai, Verena Staedtke

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Glioblastoma, Clinical and Disease Specializations > Immuno-Oncology, Technology Classifications > Therapeutic Modalities > Targets

Method to Enhance Pulmonary Dendritic Cell-mediated DNA Vaccination

Unmet NeedWith lung diseases, namely influenza and lung cancer, on the rise, pulmonary vaccination is a promising approach to elicit strong immunity to inhaled pathogens and lung cancer compared to systemic immunization strategies. In particular, inhaled DNA vaccination, a rapidly developing field, can potentially promote humoral and cellular immunity...

Published: 5/9/2024 | Inventor(s): Jung Soo Suk, Yoo Chun Kim, Justin Hanes

Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Immunotherapy, Infectious Diseases, Influenza, Lung Cancer, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Tuberculosis (TB), Vaccine

Category(s): Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB), Clinical and Disease Specializations > Infectious Diseases > Influenza, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology > Lung Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines

Local Cancer Chemo-immunotherapy Elicit Regression of Tumors

Unmet NeedThe market size for cancer immunotherapy was worth $58.1 billion in 2018, and with a CAGR of 14.5%, it is likely to reach up to $126.9 billion by 2026. Cancer immunotherapy is an extremely interesting and attractive means of extending the lifespan of patients with certain cancers. However, only about 15% of patients with advanced-stage cancer...

Published: 5/9/2024 | Inventor(s): Honggang Cui, Feihu Wang, Hao Su

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Immuno-Oncology

Artificial Lymph Nodes for T cell Immunotherapy

Unmet Need Adoptive T cell transfer immunotherapy is a promising approach for treating a variety of cancer tumors. They involve the removal, culture, and expansion of resident T cells ex-vivo several thousand fold before reinfusion back into the body. However, a concern with current culturing methods is their inconsistency in developing and retaining...

Published: 5/9/2024 | Inventor(s): Jonathan Schneck, John Hickey, Hai-Quan Mao

Keywords(s): Cancer Cells, Cancers, Cell Model, Discovery/Research Tools, Disease Indication, Immunotherapy, In Vitro Research Tool, Single, Therapeutic Matter, Therapeutic Method, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Immuno-Oncology

1 2